在众多融合领域中，"AI+医疗"无疑是最受瞩目、也最考验技术深度的赛道之一。它不仅关乎效率提升，更直接关系 到生命健康与医疗质量。 在此背景下，12月22日，格隆汇"科技赋能·资本破局"分享会揭晓了年度卓越公司评选榜单。华大基因（300676.SZ） 凭借在人工智能与基因组学领域的深度融合与创新应用，荣膺"年度卓越人工智能应用企业"。该奖项旨在表彰在人工 智能技术实现突破、并能指引行业未来发展的领军企业。 当前，医疗健康行业正加速驶入改革深水区。面对这样的趋势，华大基因以AI为驱动杠杆，持续推进从"生产型企 业"向"数据智能型企业"的战略转型。公司提出的"生成式生物智能范式"（GBI ALL），正在系统推动基因检测、健康 管理及临床诊疗迈向智能化、精准化的新阶段。 AI医疗：破解行业核心痛点 面对基因检测在临床应用中长期存在的效率瓶颈与成本压力，华大基因的AI布局精准聚焦于行业最紧迫的痛点：让精 准医疗变得更高效、更可及。 在临床诊断端，效率革命正在发生。 2024年9月，华大基因发布了行业首个面向临床的基因检测多模态大模型GeneT。如同一位不知疲倦的"AI遗传分析 师"，该模型通过百万级样本训练，能够高效 ...

AI医疗：破解行业核心痛点 从席卷全球的DeepSeek开始，一场以大模型为核心的人工智能浪潮，正以前所未有的速度从技术突破走向产业纵深。 当大多数人还在为对话机器人的"智力"惊叹时，这场变革已悄然渗透至各行各业的核心环节，重塑着价值创造的本 质。 在众多融合领域中，"AI+医疗"无疑是最受瞩目、也最考验技术深度的赛道之一。它不仅关乎效率提升，更直接关系 到生命健康与医疗质量。 在此背景下，12月22日，格隆汇"科技赋能·资本破局"分享会揭晓了年度卓越公司评选榜单。华大基因（300676.SZ） 凭借在人工智能与基因组学领域的深度融合与创新应用，荣膺"年度卓越人工智能应用企业"。该奖项旨在表彰在人工 智能技术实现突破、并能指引行业未来发展的领军企业。 当前，医疗健康行业正加速驶入改革深水区。面对这样的趋势，华大基因以AI为驱动杠杆，持续推进从"生产型企 业"向"数据智能型企业"的战略转型。公司提出的"生成式生物智能范式"（GBI ALL），正在系统推动基因检测、健康 管理及临床诊疗迈向智能化、精准化的新阶段。 面对基因检测在临床应用中长期存在的效率瓶颈与成本压力，华大基因的AI布局精准聚焦于行业最紧迫的痛点： ...

Group 1 - The core point of the news is that BGI Genomics (华大基因) is undergoing a share transfer plan initiated by its controlling shareholder, BGI Group, to raise funds for cutting-edge technology incubation [1][2] - BGI Group plans to transfer 16.73 million shares, representing 4% of the total share capital, to institutional investors with appropriate pricing and risk-bearing capabilities [1][2] - The funds raised from the share transfer will be prioritized for supporting the incubation of new productivity directions in advanced technology [2] Group 2 - BGI Genomics is positioned as the strongest platform for industrialization and commercialization within BGI Group, focusing on core advantages in reproductive health, cancer prevention, chronic disease management, and infectious disease diagnosis [3] - The company is currently in a critical business transformation period, launching new products aimed at enhancing public health and personalized health management [3] - Future growth drivers for BGI Genomics include increasing health demands due to demographic changes, urgent needs for major disease prevention, and ongoing support from policies and payment systems [3]

Core Insights - BGI Genomics launched the SEQALL comprehensive genomic solution, BGI Smart Medical System, and three core products to drive public health transformation through data and AI [2][3] - The focus is on creating a data-driven "Smart System" that ensures health benefits for everyone, leveraging technological advancements for public health [2] - The SEQALL solution addresses challenges in genetic disease detection, providing risk assessments for complex diseases during pre-pregnancy and pregnancy [2] Product and Technology Developments - The GeneT AI model, which was released last year, has served 241 institutions, while the new GeneT Agent enhances the diagnostic process with a 98% agreement rate with clinical experts and a 60.7% efficiency improvement [3] - iGeneT Pro offers interpretation support for professionals, contributing to the BGI Smart Medical System that integrates health data with clinical applications [3] Vision and Future Goals - The company emphasizes that advancements in scientific exploration are essential for improving public health and personal well-being, aiming for a future where everyone can achieve better health outcomes [5]